Peritoneal Surface Disease Severity Score as a predictor of resectability in the treatment of peritoneal surface malignancies

Yoon, William; Alame, Amer; Berri, Richard N.

doi:10.1016/j.amjsurg.2013.09.021

Cited by 32 publications

(22 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the example of PM from CRC, one such possibility for a clinical trial would be based on patient stratification using the peritoneal surface disease severity score (PSDSS) to determine resectability of those with an initial diagnosis of PM . Upon diagnosis patients would receive 2‐3 months of best systemic therapy.…”

Section: Discussionmentioning

confidence: 99%

Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions—A systematic review

Morano

Khalili

Dennis

et al. 2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

Published and ongoing U.S. and international clinical trials for CRS and HIPEC are defining important parameters that include improving patient selection, strategic sequences of treatment, cytoreductive strategies, chemotherapeutics, optimal hyperthermic temperature and timing, and toxicity profiles. Main barriers or limitations to trial development remain patient enrollment, trial design, and oncologic community collaboration. Overall progress is positive with increasing number of clinical trials throughout the world. Collaboration between surgeons and the wider oncologic community will be crucial to validate this important treatment strategy.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions—A systematic review

Morano

Khalili

Dennis

et al. 2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…In a multicenter study published in 2014, 1013 patients diagnosed with PMCO who underwent CRS and HIPEC in 609 patients were examined and PSDSS was found to be effective in predicting median survival. 12 In a series of 49 patients with heterogeneous primers by Yoon et al 13 Thirty three patients were treated with CRS and HIPEC, and PSDSS 3 and 4 were reported to be associated with unresectability. There are also studies reporting that PSDSS is effective in predicting survival in patients undergoing CRS due to ovarian and appendix mucinous neoplasm.…”

Section: Discussionmentioning

confidence: 99%

“…In single and multicenter studies, this staging system has been shown to be effective in predicting prognosis in patients with PMCO. 6,9,10,11,12,13 The aim of this study was to evaluate the validity of PSDSS in prognosis in patients who underwent CRS and HIPEC for PMCO at our center.…”

Section: Introductionmentioning

confidence: 99%

Peritoneal Disease Severity Score Predicts the Prognosis of Peritoneal Metastasis of Colorectal Origin: A 10-year Longitudinal Analysis of a Single-center Experience

Ağalar¹,

Sökmen²,

Arslan³

et al. 2019

tjcd

View full text Add to dashboard Cite

Amaç: Kolorektal kansere ikincil peritoneal metastaz (KRKPM) nedeniyle sitoredüktif cerrahi (SRC) ve hipertermik karın içi kemoterapi (HİPEK) uygulanacak hastaların değerlendirilmesinde, Peritoneal Yüzey Hastalığı Şiddet skoru (PYHŞS) kullanılmaya başlanmıştır. Bu çalışmanın amacı merkezimizde KRKPM nedeniyle SRC + HİPEK uygulanan hastalarda PYHŞS'nin prognozu öngörmedeki geçerliliğini değerlendirmektir. Yöntem: Hastaların demografik bilgileri, operatif veriler, histopatolojik özelllikler, perioperatif morbidite ve mortalite bilgileri, onkolojik izlem verileri prospektif olarak doldurulan veri tabanının retrospektif incelenmesi ile elde edildi. Hastaların preoperatif dönemdeki bilgisayarlı tomografilerinden peritoneal karsinomatozis indeks (PKİ) değerleri hesaplandı. PYHŞS klinik semptomlar, PKİ ve primer tümörün histolojisi değerlendirilerek Aim: Peritoneal Surface Disease Severity score (PSDSS) has been used in the evaluation of patients who are scheduled for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis of colorectal origin (PMCO). The aim of this study was to evaluate the validity of PSDSS in predicting prognosis in patients who underwent CRS + HIPEC for PMCO at our center. Method: Demographic data, operation data, histopathological features, perioperative morbidity and mortality, and oncologic follow-up data were obtained retrospectively from the database and analyzed. Peritoneal carcinomatosis index (PCI) values were calculated from preoperative computed tomographies. PSDSS was calculated by evaluating clinical symptoms, PCI and histology of primary tumor. Two PSDSS groups were formed: PSDSS 1 and 2 groups as low PSDSS group, and PSDSS 3 and 4 groups as high PSDSS group. Results: Sixty-one patients, including 36 females (59%) and 25 males (41%), with PMCO who underwent CRS and HIPEC were included in the study. Forty-four patients were enrolled to the low PSDSS group and 17 patients were enrolled to the high PSDSS group. Three patients (3.2%) died during the perioperative period. Twenty-one patients (34.4%) had perioperative complications. The mean follow-up was 35.0±23.2 months. During the follow-up period, 36 patients (59%) had recurrence and 44 patients (72.1%) died. The mean survival was 46.5±5.5 months, and 1-,3-and 5-year survival rates were 85%, 47% and 21%, respectively. There was no correlation between low and high PSDSS groups in terms of morbidity and recurrence (p=0.486 and p=0.385, respectively). Mortality was more frequent in high PSDSS group (94% vs 63%; p=0.024). The mean survival of patients in the low PSDSS group was significantly longer than in the high PSDSS group (57.2±6.7 months vs 16.5±2.6 months; p=0.001). Conclusion: The findings of this study demonstrated the validity of PSDSS in predicting prognosis in patients with PMCO who were scheduled for CRS and HIPEC.

show abstract

“…Risk stratification can be performed by using clinical factors that have been combined in a predictive scoring system, the Peritoneal Surface Disease Severity Score (Table 1). 19 …”

Section: Principles Of Surgerymentioning

confidence: 99%

The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases

Izquierdo¹,

Schuitevoerder²,

Plana³

et al. 2020

Cancer

View full text Add to dashboard Cite

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of colorectal cancer specifically as it relates to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. Cancer 2020;126:2534-2540.

show abstract

Peritoneal Surface Disease Severity Score as a predictor of resectability in the treatment of peritoneal surface malignancies

Cited by 32 publications

References 8 publications

Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions—A systematic review

Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions—A systematic review

Peritoneal Disease Severity Score Predicts the Prognosis of Peritoneal Metastasis of Colorectal Origin: A 10-year Longitudinal Analysis of a Single-center Experience

The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases

Contact Info

Product

Resources

About